Overall, the constellation of prognostic factors identified in our study (age, performance status, tumor multifocality/size, grade, IDH/MGMT status, and treatment modalities) closely matches the factors known in the literature to influence glioma outcomes.[23] This concordance with previously published data lends credibility to our findings and suggests that our patient cohort is representative. The gene discussed is MGMT; the disease is central nervous system cancer.